| NCT ID | NCT06362304 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Intracranial Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-04-20 |
| Primary Completion | 2025-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-04-20 with a primary completion date of 2025-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are: 1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG? 2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type? Participants will: Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.
Eligibility Criteria
Inclusion Criteria: * Patients with clinical diagnosis of brain tumor; * Be at least 18 years old; * The final pathological results could be obtained by surgery or biopsy; * Informed consent and the ability to be followed up; * Those who did not meet the exclusion criteria. Exclusion Criteria: * Insulin-dependent diabetes mellitus or fasting blood glucose \>7 mmol/L before 99mTc-CNDG injection; * Severe liver or kidney disease (serum creatinine level \>3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal); * Severe hypersensitivity or hypersensitivity to radiocontrast agents; * Claustrophobia (inability to undergo SPECT/CT or PET/CT scans); * Patients receiving radiotherapy and chemotherapy; * Being pregnant or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06362304 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intracranial Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06362304 currently recruiting?
Yes, NCT06362304 is actively recruiting participants. Contact the research team at 13611093752@163.com for enrollment information.
Where is the NCT06362304 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06362304 clinical trial?
NCT06362304 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 30 participants.